ARTICLE | Company News
Targeted Genetics other research news
February 21, 1995 8:00 AM UTC
The Seattle company received a $100,000 Phase I SBIR from the National Institutes for Diabetes, Digestive and Kidney Disorders to develop a manufacturing process capable of efficiently producing large quantities of clinical grade AAV vectors to treat cystic fibrosis. ...